{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"613"},{"groupId":"OG001","value":"594"}]}],"title":"At least 1 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"495"},{"groupId":"OG001","value":"444"}]}],"title":"At least 1 Grade 3, 4, or 5 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"262"}]}],"title":"At least 1 treatment-emergent SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"32"}]}],"title":"TEAE leading to study drug discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"35"}]}],"title":"TEAE leading to death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"428"},{"groupId":"OG001","value":"451"}]}],"title":"Deaths While On Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"58"}]}],"title":"Deaths During 30 Days Post Last Dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"627"},{"groupId":"OG001","value":"618"}],"units":"Participants"}],"description":"Data presented are the number of participants who experienced at least 1 TEAE, Grade 3, 4, or 5 TEAE, treatment-emergent serious adverse event (SAE), TEAE leading to discontinuation of study treatment (ramucirumab/placebo or docetaxel), and TEAE leading to death. Clinically significant events were defined as treatment-emergent SAEs and other non-serious adverse events (AEs) regardless of causality. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.","groups":[{"description":"On Day 1 of each 21-day cycle, participants received ramucirumab DP followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Ramucirumab DP: 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG000","title":"Ramucirumab and Docetaxel"},{"description":"On Day 1 of each 21-day cycle, participants received placebo followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Placebo (matching Ramucirumab DP): 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG001","title":"Placebo and Docetaxel"}],"paramType":"NUMBER","populationDescription":"Safety population: Randomized participants who received any quantity of study drug, grouped by the treatment they actually received.","reportingStatus":"POSTED","timeFrame":"First infusion up to 30 days following last infusion (up to Cycle 38, 21 days/cycle)","title":"Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs) or Died","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"participants"}